Details for New Drug Application (NDA): 005914
✉ Email this page to a colleague
NDA 005914 describes PBZ, which is a drug marketed by Novartis and is included in three NDAs. Additional details are available on the PBZ profile page.
The generic ingredient in PBZ is tripelennamine hydrochloride. There is one drug master file entry for this compound. Additional details are available on the tripelennamine hydrochloride profile page.
The generic ingredient in PBZ is tripelennamine hydrochloride. There is one drug master file entry for this compound. Additional details are available on the tripelennamine hydrochloride profile page.
Summary for 005914
| Tradename: | PBZ |
| Applicant: | Novartis |
| Ingredient: | tripelennamine hydrochloride |
| Patents: | 0 |
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 50MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 004
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | ELIXIR;ORAL | Strength | EQ 25MG HYDROCHLORIDE/5ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
